Life Sciences

  • February 26, 2026

    Chancery Asked To OK $7.6M Deal To End $1.5B De-SPAC Row

    Stockholders of special purpose acquisition company HighCape Capital LP have sought Delaware Court of Chancery approval for a $7.6 million settlement of a class suit accusing company principals of pursuing an overpriced take-public merger of biopharmaceutical tech company Quantum-Si, in litigation complicated by an unusual discovery stumble.

  • February 26, 2026

    Boston Scientific Wins Toss Of Spinal Device Suit

    Boston Scientific escaped a suit alleging that its spinal implant device malfunctioned and caused a Michigan man pain and permanent injuries, after a federal judge ruled that each of the plaintiff's claims are preempted by federal law.

  • February 26, 2026

    Kenvue Can't Duck Texas AG's Tylenol Autism Suit

    A Texas state court Thursday rejected Kenvue's bid to toss a lawsuit that Texas' attorney general has brought alleging Tylenol taken during pregnancy could cause autism in children, even though it is marketed as the safest pain relief for pregnant women and young children.

  • February 26, 2026

    $200M Antitrust Deal Can Shield Drugmakers In States' Claims

    Sun Pharmaceutical and Taro Pharmaceuticals can use their $200 million settlement with the "end payors" for generic drugs in an alleged price-fixing scheme as a defense in a similar lawsuit brought by 47 states and territories, the Connecticut federal judge overseeing the case ruled Wednesday.

  • February 26, 2026

    Life Sciences Group Of The Year: Covington

    Covington & Burling LLP's recent work advising Novartis on its $12 billion acquisition of Avidity Biosciences Inc., boosting the Swiss pharmaceutical giant's neuroscience portfolio, is among the reasons the firm landed among the 2025 Law360 Life Sciences Groups of the Year.

  • February 26, 2026

    Hawaii Officials Fight Claim That Hemp Law Violates Farm Bill

    Hawaii's attorney general and health department director are urging a federal court to throw out a challenge to new hemp regulations, arguing that they have immunity under the 11th Amendment and that the regulations don't conflict with the Agriculture Improvement Act of 2018, also known as the Farm Bill.

  • February 26, 2026

    Feds Back Pharma In 340B Contract Pharmacy Disputes

    State laws that block drugmakers from imposing restrictions on federally funded hospitals and the contract pharmacies they use to dispense discounted drugs under the 340B drug discount program are violating federal law, the Trump administration said, siding with manufacturers in their bid to strike down these laws.

  • February 25, 2026

    Online Abortion Pill Provider Illegally Ships To Texas, AG Says

    Texas Attorney General Ken Paxton sued Aid Access, its founder and a California doctor in state court Tuesday alleging they operate an "abortion-by-mail enterprise" that ship abortion-inducing drugs to Texas residents, which is endangering the lives of unborn children and their mothers. 

  • February 25, 2026

    White House Cites Fraud, Freezes $259M In Minn. Medicaid

    The Trump administration on Wednesday said it would hold back $259.9 million in Medicaid funding for Minnesota as part of what it called an unprecedented effort to combat fraud in programs that support low-income families.

  • February 25, 2026

    Fed. Circ. Gene Therapy Ruling Gives Rare Eligibility Clarity

    When the Federal Circuit revived the University of Pennsylvania's gene therapy patent last week, it provided a bright-line rule that's often missing in the debate over patent eligibility, attorneys say.

  • February 25, 2026

    $17.9M Drug Price-Fixing Deal Advances Despite Objections

    A Connecticut federal judge on Wednesday advanced a $17.9 million generic drug price-fixing settlement between 48 states and territories and pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc. and Lannett Co. Inc., sidelining objections by consumers suing separately in a Pennsylvania multidistrict litigation case.

  • February 25, 2026

    Birth Control Shot Plaintiffs Lose Mid-Case Appeal Bid In Del.

    The Delaware Supreme Court has refused to hear an interlocutory appeal in product liability litigation over the contraceptive injection Depo-Provera, leaving in place a set of case-management orders designed to streamline what is expected to become hundreds of lawsuits in the state.

  • February 25, 2026

    NJ Judge Trims J&J And Neutrogena Benzene Suit

    A New Jersey federal judge has slashed state and common law claims in a multistate proposed class action alleging that acne cream produced by Johnson & Johnson Consumer Inc. and Kenvue Inc. contained a cancer-causing chemical without warning labels, saying the buyers' claims missed "a step" and were "circular."

  • February 25, 2026

    9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case

    The Ninth Circuit ruled against a lower court Wednesday in saying pharmaceutical giant Eli Lilly does not owe $278 million in royalties to an Arizona company for insulin-brands sales, saying an agreement between the companies did not cover insulin products Eli Lilly made using a certain yeast expression technology.

  • February 25, 2026

    Philly Says PBMs Can't Exit Suit Over Opioid Crisis

    The city of Philadelphia on Wednesday defended its lawsuit against CVS Health Corp. and other pharmacy benefit managers over allegedly fueling the opioid crisis, urging a Pennsylvania federal judge to reject the PBMs' arguments that they should be let out of the litigation for lack of a valid legal claim.

  • February 25, 2026

    Hagens Berman Fights Fee Demand Amid Misconduct Claims

    Hagens Berman Sobol Shapiro LLP has blasted as premature a bid from drugmakers in Pennsylvania federal court calling for the firm to cover the fees and costs of a special master who alleged the firm committed misconduct in product liability actions over the morning sickness drug thalidomide.

  • February 25, 2026

    Life Sciences Group Of The Year: Davis Polk

    Davis Polk & Wardwell LLP attorneys advised Intra-Cellular Therapies Inc. on its $14.6 billion sale to Johnson & Johnson, guided Endo Inc. through its $6.7 billion merger with Mallinckrodt PLC and advised Novo Nordisk in its proposed $9.1 billion acquisition of Metsera, earning it a spot among the 2025 Law360 Life Sciences Groups of the Year. 

  • February 25, 2026

    Taft Adds 5-Person IP Team From McAndrews Held

    Taft Stettinius & Hollister LLP announced on Wednesday that it has hired a group of four attorneys and one patent agent from McAndrews Held & Malloy Ltd. in the Chicago, Minneapolis and West Palm Beach, Florida, offices.

  • February 25, 2026

    Budtender Alleges Dispensary Gives Tips To Managers

    A proposed class of budtenders is suing an Illinois dispensary and its management company, saying they violate state and federal labor law by pooling tips and distributing them to managers as well as the budtenders.

  • February 25, 2026

    Moderna's Damages Expert Limited In March Patent Trial

    Moderna's damages expert was blocked from offering testimony about what a reasonable royalty would be in a suit alleging its COVID-19 vaccine infringed a rival's patents, after a federal judge found that part of the testimony wasn't reliable.

  • February 25, 2026

    Novo's $2.1B Vivtex Deal Boosts Obesity Drug Pipeline

    Novo Nordisk said on Wednesday it is partnering with Vivtex Corp. on a deal worth up to $2.1 billion to develop drugs for obesity and related conditions, pressing ahead with a weight loss-drug franchise that has delivered rapid growth alongside regulatory scrutiny and courtroom clashes.

  • February 24, 2026

    9th Circ. Grants Atty Fee Appeal In Eye Drop Pricing Suit

    District courts cannot reduce fee awards to attorneys based on a firm's size, the Ninth Circuit ruled in a published opinion Tuesday, sending a case back to a California federal court to recalculate attorney fees awarded to a "small" firm that represented wholesalers in a Robinson-Patman Act suit against eye drop manufacturers.

  • February 24, 2026

    Ariz., Calif. Lead Suit Over 'Senseless' HHS Vaccine Overhaul

    Arizona and California are leading a coalition of states challenging the U.S. Department of Health and Human Services' decision to cut vaccine recommendations for American children, alleging in a lawsuit Tuesday that the "unprecedented attack" stems from HHS Secretary Robert F. Kennedy Jr.'s "unscientific hostility to vaccines."

  • February 24, 2026

    Ex-Med School Dean Claims Fla. College Broke Work Contract

    The former dean of Florida International University's medical school told a state court that the university breached his employment contract by refusing to pay him the salary promised in their agreement and undermined his independence.

  • February 24, 2026

    Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit

    Two former Mallinckrodt executives have escaped the only remaining claims they faced in an investor suit tied to the company's 2023 bankruptcy and share cancellations after a New Jersey federal judge said he made a "clear error" keeping them in the suit last year.

Expert Analysis

  • Protecting Sensitive Court Filings After Recent Cyber Breach

    Author Photo

    In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.

  • Series

    Judging Figure Skating Makes Me A Better Lawyer

    Author Photo

    Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.

  • Trending At The PTAB: Petitioners' Settled Expectations

    Author Photo

    Recent Patent Trial and Appeal Board decisions show that the U.S. Patent and Trademark Office's new "settled expectations" factor is no longer the exclusive domain of patent owners and can also provide petitioners with viable pathways to argue against discretionary denial, say attorneys at Finnegan.

  • 9th Circ. Ruling May Help Pharma Cos. Avert Investor Claims

    Author Photo

    The Ninth Circuit's recent decision affirming the dismissal of a securities fraud class action alleging that Talphera deceived investors by marketing a drug with a misleading slogan should give plaintiffs pause before filing similar complaints where snappy slogans are accompanied by copious clarifying information, say attorneys at Simpson Thacher.

  • What Ethics Rules Say On Atty Discipline For Online Speech

    Author Photo

    Though law firms are free to discipline employees for their online commentary about Charlie Kirk or other social media activity, saying crude or insensitive things on the internet generally doesn’t subject attorneys to professional discipline under the Model Rules of Professional Conduct, says Stacie H. Rosenzweig at Halling & Cayo.

  • Junior Attys Must Beware Of 5 Common Legal Brief Mistakes

    Excerpt from Practical Guidance
    Author Photo

    Junior law firm associates must be careful to avoid five common pitfalls when drafting legal briefs — from including every possible argument to not developing a theme — to build the reputation of a sought-after litigator, says James Argionis at Cozen O'Connor.

  • Opinion

    State AGs, Not Local Officials, Should Lead Public Litigation

    Author Photo

    Local governments’ public nuisance lawsuits can raise constitutional and jurisdictional challenges, reinforcing the principle that state attorneys general — not municipalities — are best positioned to litigate on behalf of citizens when it is warranted, says former Utah Attorney General John Swallow.

  • 3rd Circ. Clarifies Ch. 11 3rd-Party Liability Scope Post-Purdue

    Author Photo

    A recent Third Circuit decision that tort claims against the purchaser of a debtor's business belong to the debtor's bankruptcy estate reinvigorates the use of Chapter 11 for the resolution of nondebtor liability in mass tort bankruptcies following last year's U.S. Supreme Court ruling in Purdue Pharma, say attorneys at Sullivan & Cromwell.

  • Texas Suit Marks Renewed Focus On Service Kickback Theory

    Author Photo

    After a dormant period at the federal level, a theory of kickback enforcement surrounding nurse educator programs and patient support services resurfaced with a recent state court complaint filed by Texas against Eli Lilly, highlighting for drugmakers the ever-changing nature of enforcement priorities and industry landscapes, say attorneys at Sheppard Mullin.

  • Series

    Power To The Paralegals: How And Why Training Must Evolve

    Author Photo

    Empowering paralegals through new models of education that emphasize digital fluency, interdisciplinary collaboration and human-centered lawyering could help solve workforce challenges and the justice gap — if firms, educators and policymakers get on board, say Kristine Custodio Suero and Kelli Radnothy.

  • Series

    Playing Softball Makes Me A Better Lawyer

    Author Photo

    My time on the softball field has taught me lessons that also apply to success in legal work — on effective preparation, flexibility, communication and teamwork, says Sarah Abrams at Baleen Specialty.

  • 5 Years In, COVID-19 Fraud Enforcement Landscape Is Shifting

    Author Photo

    As the government moves pandemic fraud enforcement from small-dollar individual prosecutions to high-value corporate cases, and billions of dollars remain unaccounted for, companies and defense attorneys must take steps now to prepare for the next five years of scrutiny, says attorney David Tarras.

  • Fed. Circ. In August: A Framework For AIA Derivation Disputes

    Author Photo

    In Global Health Solutions v. Selner, the Federal Circuit established how to assess derivation challenges under the America Invents Act's first-to-file system, making it easier for petitioners to determine a challenge's odds of success, say attorneys at Knobbe Martens.

  • USPTO's Track One A Reliable Patent Pathway Amid Backlog

    Author Photo

    As the U.S. Patent and Trademark Office faces a backlog of unexamined utility, plant and reissue patent applications, patent applicants should consider utilizing the USPTO's Track One Program, which not only expedites the process but also increases the likelihood of working with more senior examiners, says Ryan Schermerhorn at Marshall Gerstein.

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.